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Abstract
Pulmonary hypertension is defined as a mean arterial pressure of ≥25 mmHg as confirmed 
on right heart catheterisation. Traditionally, the pulmonary arterial systolic pressure has 
been estimated on echo by utilising the simplified Bernoulli equation from the peak 
tricuspid regurgitant velocity and adding this to an estimate of right atrial pressure. Previous 
studies have demonstrated a correlation between this estimate of pulmonary arterial 
systolic pressure and that obtained from invasive measurement across a cohort of patients. 
However, for an individual patient significant overestimation and underestimation can occur 
and the levels of agreement between the two is poor. Recent guidance has suggested that 
echocardiographic assessment of pulmonary hypertension should be limited to determining 
the probability of pulmonary hypertension being present rather than estimating the 
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pulmonary artery pressure. In those patients in whom the presence of pulmonary 
hypertension requires confirmation, this should be done with right heart catheterisation 
when indicated. This guideline protocol from the British Society of Echocardiography aims 
to outline a practical approach to assessing the probability of pulmonary hypertension 
using echocardiography and should be used in conjunction with the previously published 
minimum dataset for a standard transthoracic echocardiogram.
Introduction
The British Society of Echocardiography (BSE) Education 
Committee has previously published a minimum dataset 
for a standard adult transthoracic echocardiogram (1). This 
document specifically states that the minimum dataset 
is usually only sufficient when the echocardiographic 
study is entirely normal. However, the BSE Education 
Committee has published a number of supplementary 
guidelines to cover specific pathologies to be utilised in 
conjunction with this minimum dataset.
The intended benefits of such supplementary 
recommendations are to:
 • Support cardiologists and echocardiographers to 
develop local protocols and quality control programmes 
for an adult transthoracic study.
 • Promote quality by defining a set of descriptive terms 
and measurements, in conjunction with a systematic 
approach to performing and reporting a study in 
specific disease states.
 • Facilitate the accurate comparison of serial 
echocardiograms performed in patients at the same or 
different sites.
In this guideline, the important measurements that 
should be performed when assessing a patient’s 
probability of having pulmonary hypertension (PH) are 
discussed. Some of these views are part of the minimum 
dataset but the majority are additional. The aim of this 
document is to provide practical recommendations 
for the image and analysis dataset required in patients 
being assessed for possible PH, or where the diagnosis 
is known and is consistent with the 2015 European 
Society of Cardiology/European Respiratory Society 
recommendations on the diagnosis and treatment 
of PH (2). Estimation of PH in patients with left heart 
disease such as valvular heart disease remains within 
current guidelines (3, 4, 5). Estimation of pulmonary 
artery pressure (PAP) within these patients is reasonable, 
at rest and during exercise (3, 6) or during follow-up 
of an individual patient. However, confirmation with 
right heart catheterisation (RHC) should be considered, 
particularly if the presence of PH is a major component 
of any decision to refer for intervention.
This guideline replaces the previous protocol on PH 
published by the BSE and will be reviewed and updated 
in the future as a result of future publications or changes 
in best practice.
Background
PH is presently defined as an increase in mean pulmonary 
arterial pressure to ≥25 mmHg at rest as assessed by right 
heart catheterisation (2). The clinical significance of a 
mean pulmonary arterial pressure between 21 mmHg 
and 24 mmHg is unclear. It can complicate many 
cardiovascular, respiratory and connective tissue diseases. 
Untreated, morbidity and mortality levels are high (7, 8) 
and therefore accurate and prompt diagnosis is crucial. 
The diagnosis of PH requires a clinical suspicion based 
on symptoms, physical examination and review of a 
comprehensive set of investigations. Echocardiography is 
a key imaging modality in the assessment of patients with 
suspected or known PH.
The classification of PH categorises different 
clinical conditions into five groups (Table  1). This is 
an important categorisation for two reasons: first, 
the most common form of PH encountered in any 
echocardiography department will be secondary 
to left heart disease (9) and hence a full study with 
consideration of indirect measures of elevation 
in left ventricular end-diastolic pressure must be 
performed in all cases consistent with the minimum 
dataset (1); secondly, the interpretation of supportive 
measurements for classification of patients with 
intermediate probability of PH, such pulmonary artery 
acceleration/mid systolic notching, must be taken in 
the context of the possible underlying cause as these 
may be more likely in cases with pre-capillary PH.
Each of these groups can further be categorised as 
to whether there is normal pulmonary arterial wedge 
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pressure (an estimate of left atrial pressure) or elevated 
pulmonary arterial wedge pressure, which may be helpful 
in identifying the aetiology of PH. The World Health 
Classification of PH is outlined in Table 1.
The traditional echocardiographic approach to 
estimating pulmonary artery systolic pressure (PASP) 
uses a derivation of right ventricular pressure from 
the tricuspid regurgitation (TR) velocity added to a 
qualitative assessment of right atrial pressure (RAP). 
Previous studies have demonstrated good correlation 
across patient populations but only moderate precision 
of absolute PASP values calculated from TR velocity 
(TRV)max (11, 12, 13, 14). This is important as in an 
individual patient, significant under and over estimation 
can occur leading to misdiagnosis and inappropriate 
treatment (15).
There are number of reasons why the level of 
agreement between the estimated pressures derived 
by echocardiography and those measured invasively is 
poor. First, errors may occur in accurate measurement 
of the peak TRV signal. This can result in both over 
estimation and underestimation if the quality of the 
Doppler signals is poor or inaccurate as a result of 
suboptimal Doppler alignment due to eccentric jets. 
When estimating right ventricular systolic pressure 
(RVSP) from the TRV using the Bernoulli equation, 
the TRV is squared and multiplied by 4, so even small 
errors in the absolute measurement of TRV can result in 
significant changes to the estimate of RVSP. Secondly, 
in order to obtain an estimate of PASP, the RVSP 
needs to be added to an estimate of the RAP derived 
from measurement of the inferior vena cava (IVC) 
dimensions and response to inspiration. However, in 
many patients, IVC dimensions cannot be obtained 
and even in those where measurement is possible, the 
accuracy between echo estimation of RAP and invasive 
measurement is as low as 34% (16). Thirdly, it is well 
recognised that in patients with severe free-flowing TR 
that the correlation between TRV and RVSP is poor and 
should not be performed (17). In addition, absence of 
TR is insufficient to exclude the presence of PH. For 
example, one study has shown that in patients with 
scleroderma being screened for PH, if a TRV cut-off 
of 2.7 m/s was used, this would have excluded some 
patients who had a mean pulmonary arterial pressure 
>40 mmHg (18). Furthermore, the expected normal 
upper limit of PASP depends on BMI (19).
In view of these factors, when screening patients 
with suspected PH, information obtained from 
echocardiography can only grade the probability of PH 
being present rather than provide a definitive diagnosis. 
Therefore, when assessing the probability of PH, the 
measurement of TRV should be used in conjunction 
with other echocardiographic markers of PH. Thus, the 
information in this protocol is intended to be used as 
a guide and the data have been selected by consensus 
using as much evidence base as possible. Future 
studies assessing the accuracy of this probability-based 
approach in the diagnosis of PH will be beneficial and 
add to the evidence base. The invasive measurement of 
Table 1 Classification of PH.
WHO 
group
 
Aetiology of pulmonary hypertension
Mean pulmonary 
arterial wedge pressure
 
Example causes
1 
 
 
Pulmonary arterial hypertension 
 
 
Normal 
 
 
Idiopathic, hereditary, drug or toxin induced, shunts 
related to congenital heart disease, connective tissue 
disease, portal hypertension, chronic haemolytic 
anaemia
2 
 
 
Pulmonary hypertension secondary 
to left heart disease 
 
Increased 
 
 
Valvular heart disease, systolic dysfunction, diastolic 
dysfunction, pericardial disease, congenital/acquired 
left heart inflow/outflow tract obstruction, congenital 
cardiomyopathies
3 
 
 
Pulmonary hypertension secondary 
to lung disease 
 
Normal 
 
 
Chronic obstructive pulmonary disease, severe asthma, 
interstitial lung disease, sleep apnoea, long term 
exposure to high altitude, congenital lung 
abnormalities
4 Chronic thromboembolic 
pulmonary hypertension (CTEPH)
Normal Chronic pulmonary embolism 
5 
 
Pulmonary hypertension with 
unclear and/or multifactorial 
mechanisms
Normal or increased 
 
Systemic diseases, sarcoidosis, vasculitis, haematological 
malignancies, chronic renal failure, metabolic 
disorders, lung tumours
Adapted from World Health Organisation Classification of PH (10).
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pulmonary artery pressure during right heart cardiac 
catheterisation is required to confirm or refute a 
diagnosis of PH.
The first step in assessing the echocardiographic 
probability of PH being present is to measure the peak 
TRV. If this is a good-quality signal and is greater than 
3.4 m/s, there is a high probability of PH being present. 
If the peak TRV is below 3.4 m/s, the probability of PH 
is assessed in combination with other echocardiographic 
markers.
This approach based on estimation of likelihood is 
recommended for all clinical groups of PH. Additional 
considerations in specific subsets of patients are included 
in the ‘Appendices’ section. The assessment of probability 
of PH by echocardiography is just one part in the overall 
clinical judgement as to the presence of PH in a certain 
individual. Echocardiographic findings should be 
interpreted alongside other clinical findings to establish 
the likelihood of PH prior to confirmatory diagnosis as 
needed by RHC.
Echocardiographic assessment of patents 
with PH
The flow chart depicted in Fig.  1 is used to assess the 
probability of PH. The echocardiographic parameters used 
for grading the probability of PH are set out in Table 2 and 
described further in Table 3. If the TRV is >3.4 m/s then 
the echocardiographic probability of PH is high. If the 
TRV is ≤3.4 m/s, then other echocardiographic parameters 
suggesting PH must be used to assign the probability of 
PH. These parameters are split into three categories (A: the 
ventricles; B: the pulmonary artery; C: the IVC and right 
atrium). Parameters from at least two different categories 
are needed to determine the probability of PH.
Echocardiography also provides information about 
aetiology and prognosis in patients with PH. Patients 
with established PH or high probability for PH should 
have full assessment to exclude left-sided heart disease or 
intracardiac shunts as the cause of PH. Right ventricular 
dilatation and dysfunction are considered poor prognostic 
markers in patients with PH. Additional measurements that 
can be used to assess patients with PH are shown in Table 4.
TR velocity
 2.8 m/s or
not measureable
LOW INTERMEDIATE HIGH
> 2.8 &  3.4 m/s > 3.4 m/s
 2 echo
categories
 2 echo
categories
No NoYes Yes
Figure 1
Flow chart to assess the probability of pulmonary hypertension using 
parameters identified from within ≥2 categories (the ventricles, 
pulmonary artery or the inferior vena cava and right atrium) in 
conjunction with tricuspid regurgitation velocity. Adapted from ESC/ERS 
Guidelines for the diagnosis and treatment of pulmonary hypertension 
2015 (2).
Table 2 Echocardiographic signs used to help grade the probability of PH.
A: The ventriclesa B: Pulmonary arterya C: Inferior vena cava and right atriuma
Right ventricle/left ventricle basal diameter 
ratio >1.0 
 
Right ventricular outflow Doppler 
acceleration time <105 ms and/or 
mid systolic notching 
Inferior vena cava diameter >21 mm with 
decreased inspiratory collapse (<50% 
with a sniff or <20% with quiet 
respiration)
Flattening of the interventricular septum (left 
ventricular eccentricity index >1.1 in systole 
or both systole and diastole)
Early diastolic pulmonary 
regurgitation (PR) velocity >2.2 m/s 
Right atrial area (end systole) >18 cm2 
 
PA diameter >25 mm
aEchocardiographic parameters from at least two different categories (A/B/C) from the list should be present to alter the level of echocardiographic 
probability of pulmonary hypertension.
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Table 3 Minimum requirements needed to assess the probability of pulmonary hypertension.
Measurements View (modality) Explanatory note Image
Peak TR velocity A4C
PSAX/RV 
inflow (CW)
Peak TRV is measured by CW Doppler across the 
tricuspid valve. Multiple views may need to be 
taken to obtain the optimal window. These 
include the RV inflow, parasternal short axis 
(PSAX), apical 4-chamber (A4C) view, subcostal 
view or a modified view between the PSAX 
and A4C (20)
Ensure the CW Doppler to flow angle is 
correctly aligned. Eccentric jets can lead to 
incomplete Doppler envelopes and 
underestimation of TR velocity. A high sweep 
speed (100 mm/s) (21) can help to differentiate 
between true velocities and artefact
Velocity can be under estimated in severe/free 
TR and should be stated in the report (see 
‘Appendices’ section)
Measure from a complete TR envelope. Choose 
the highest velocity (average of five beats in 
atrial fibrillation)
A TRV <2.8 m/s is considered normal (2, 22)
Pulmonary artery 
(PA) diameter
PSAX (2D) PA dimension is measured in end diastole 
halfway between the PV and bifurcation of 
main PA (21)
The PA dilates in response to volume and 
pressure overload
A diameter of >25 mm is considered  
abnormal (2)
RV outflow tract 
(RVOT) 
acceleration 
time (AT)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PSAX (PW) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A pulsed wave (PW) Doppler measurement 
taken after positioning the sample volume just 
below the pulmonic cusp on the RV side in the 
RV outflow tract (23)
Measure at end expiration from the onset of 
flow to peak flow velocity. As pulmonary 
artery pressure (PAP) increases, the 
acceleration time of the RV ejection into the 
PA shortens
Use the average of five beats in atrial 
fibrillation. Heart rates outside of the normal 
range (<70 or >100 bpm) may reduce accuracy 
and a correction for heart rate (HR) may be 
used (RVOT AT × 75/HR) (24, 25, 26)
When pulmonary pressures measured invasively 
are >25 mmHg, changes in heart rate have no 
significant effect on acceleration time (25)
Acceleration time of <105 ms is considered a 
marker of raised PAP (27)
 
 
 
 
 
 
 
(Continued)
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Measurements View (modality) Explanatory note Image
Early diastolic PR 
velocity
PSAX or 
parasternal 
RV outflow 
view (CW) 
A CW Doppler measurement through the 
pulmonary valve in line with the PR jet. 
Multiple views may be needed to obtain the 
best PR signal. The peak (early/beginning of 
diastole) PR velocity (PRVBD) value is measured. 
This may have additional value when TRV 
cannot be used or relied upon
An early PR velocity >2.2 m/s is considered a 
marker of raised mean PAP (2)
Pulmonary systolic 
notch
PSAX (PW) A PW Doppler measurement taken after 
positioning the sample volume just below the 
pulmonic cusp on the RV side in the RV outflow 
tract (15)
Increased pulmonary vascular resistance and 
pulmonary arterial stiffness can cause a 
reflection of waves which return towards the 
RV during systole. This impedes RV ejection 
and causes ‘notching’ of the Doppler profile
The presence of a pulmonary systolic notch is 
considered a marker of raised PAP
The presence of a pulmonary mid systolic notch 
is more likely to represent increased pulmonary 
vascular resistance and poor vascular 
compliance in keeping with pre-capillary PH, 
rather than PH due to left heart disease (28)
Eccentricity  
index (EI)
PSAX (2D) Measure from PSAX view at mid LV level 
between papillary muscle and tips of mitral 
valve leaflets. End systole is taken as the frame 
with the smallest LV cavity; end diastole is 
measured on the peak of the R-wave (29)
The ratio of the minor axis dimensions as shown 
in the image (D2/D1) measured at end systole 
and end diastole. D1 = left ventricular diameter 
perpendicular to the septum; D2 = left 
ventricular diameter parallel to the septum
RV pressure and volume overload can lead to an 
abnormal shape and function of the 
interventricular septum, resulting in flattening
RV volume overload causes eccentricity in 
diastole only. RV pressure overload also causes 
eccentricity in systole. Off-axis PSAX images 
may cause artefactual eccentricity
Left ventricular eccentricity index
>1.1 is considered abnormal (2)
RV/LV basal 
diameter ratio 
 
 
 
 
 
 
 
 
 
A4C (2D) 
 
 
 
 
 
 
 
 
 
 
This is measured from the standard A4C view 
without foreshortening. Measurement is taken 
at end diastole
Ratio of >1 measured at end diastole suggests 
RV dilatation (2) 
 
 
 
 
 
 
Table 3 Continued.
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Measurements View (modality) Explanatory note Image
Right atrial area A4C (2D) Measure at end ventricular systole on the frame 
just prior to tricuspid valve opening
Trace the RA from the plane of the TV annulus 
along the IAS, superior and lateral walls of RA
RAA >18 cm2 is considered abnormal (21, 30)
 
Inferior vena cava 
diameter (IVC) 
 
 
 
 
 
 
 
 
 
 
 
Subcostal (2D 
M-mode) 
 
 
 
 
 
 
 
 
 
 
 
Diameter is measured perpendicular to the IVC 
long axis, 1–2 cm from the RA junction at end 
expiration
Assess size and percentage reduction in 
diameter with sniffing or quiet inspiration
IVC diameter >21 mm with decreased inspiratory 
collapse (<50% with a sniff or <20% with 
quiet respiration) is considered abnormal (2) 
 
 
 
 
 
Table 3 Continued.
Additional measurements
Although not required when determining the likelihood 
of PH being present, a number of other echo markers 
can be useful in determining the severity of PH and may 
provide additional prognostic information (Table  4). 
These are particularly useful in those patients with a 
confirmed diagnosis of PH. These markers include right 
ventricular dimensions (RVD1 RVD2, RVD3), fractional 
area change and tricuspid annular plane systolic excursion 
(TAPSE). In addition, the peak systolic RV pulsed tissue 
Doppler velocity taken at the lateral tricuspid annulus 
and right ventricular index of myocardial performance 
(RIMP) can provide further information.
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Table 4 Useful additional features and prognostic findings in patients with established PH.
Measurements View (modality) Explanatory note Image
Pericardial effusion All views (2D) The presence of a pericardial effusion 
due to PH is a sign of advanced disease 
with poor prognosis (31, 32)
RV dimensions (RVD1, 
RVD2, RVD3)
A4C (2D) Due to increasing preload and 
afterload, progressive right ventricular 
dilatation is seen with worsening 
pulmonary hypertension
All measurements are taken at end 
diastole in the RV-focused view (33). 
RV size may be underestimated due to 
the crescentric RV shape
RVD1: Basal RV diameter. Measured at 
the maximal transverse diameter in the 
basal one third of the RV. RVD1 
>41 mm is abnormal (33)
RVD2: Mid RV diameter measured at 
the level of the LV papillary muscles
RVD2 >35 mm is abnormal (33)
RVD3: RV length (end diastole from the 
plane of the tricuspid annulus to the 
RV apex)
RVD3 >83 mm is abnormal (33)
Fractional area change 
(FAC)
A4C (2D) Manual tracing of the RV endocardial 
border from the lateral tricuspid 
annulus along the free wall to the 
apex and back along the 
interventricular septum to medial 
tricuspid valve annulus at end diastole 
and end systole. A disadvantage of this 
measure is that it neglects the 
contribution of the RV outflow tract to 
overall systolic function
FAC = (RVAd − RVAs)/RVAd
RV FAC <35% indicates RV systolic 
dysfunction (33)
RV pulsed tissue 
Doppler S wave (Sʹ) 
velocity 
 
 
 
 
 
 
 
 
 
 
 
A4C (PW TDI) 
 
 
 
 
 
 
 
 
 
 
 
 
 
PW tissue Doppler S wave measurement 
taken at the lateral tricuspid annulus 
in systole. It is important to ensure the 
basal RV free wall segment and the 
lateral tricuspid annulus are aligned 
with the Doppler cursor to avoid 
velocity underestimation
A disadvantage of this measure is that 
it assumes that the function of a single 
segment represents the function of the 
entire ventricle, which is not likely in 
conditions that include regionality 
such as RV infarction (21)
Sʹ wave velocity <9.5 cm/s indicates RV 
systolic dysfunction (33)
(Continued)
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Measurements View (modality) Explanatory note Image
Myocardial performance 
index (RIMP)
A4C (PW or PW 
TDI)
RIMP is an index of global RV 
performance. The isovolumic 
contraction time (IVCT), isovolumic 
relaxation time (IVRT) and ejection 
time intervals can be measured using 
tissue Doppler or pulsed wave Doppler
Pulsed wave Doppler or tissue Doppler 
methods require a sample positioned 
at the lateral tricuspid valve annulus. 
However, RIMP derived from pulsed 
wave Doppler also requires an 
additional sample from the RVOT and 
both pulse wave samples need to have 
near-identical R-R intervals (i.e. heart 
rate). Tissue Doppler is preferred as it 
is derived from a single sample
RIMP >0.43 by pulsed wave Doppler or 
>0.54 by tissue Doppler indicates RV 
dysfunction (33)
Tissue Doppler values >0.64 are 
associated with worse prognosis (32)
Tricuspid Annular Plane 
Systolic Excursion 
(TAPSE) 
 
 
 
 
 
 
 
 
 
A4C (M-mode) 
 
 
 
 
 
 
 
 
 
 
 
This is an angle dependent 
measurement and therefore it is 
important to align the M-mode cursor 
along the direction of the lateral 
tricuspid annulus. Select a fast sweep 
speed
The excursion of the lateral tricuspid 
annulus is measured by M-mode 
between end diastole and peak systole
A measure of longitudinal RV systolic 
function. TAPSE <1.7 cm is highly 
suggestive of RV systolic  
dysfunction (33)
 
Table 4 Continued.
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Other echocardiographic measurements
In addition to the echocardiographic measures discussed 
in this document, there are other echocardiographic 
markers that may be of use in assessing patients with PH. 
These measures include stroke volume, cardiac output 
and pulmonary vascular resistance, although the value 
of serial measures of these by echocardiography has not 
been validated. These measures may be of value where 
further haemodynamic information is required:
 • Pulmonary arterial end-diastolic pressure (PDP). 
Measure pulmonary regurgitant jet velocity taken at 
end diastole (PRVED) (Fig. 2).
PDP = 4(PRVED)2 + RAP
 • Mean pulmonary artery pressure (31). Measure 
pulmonary regurgitant jet velocity taken at the 
beginning of diastole (PRVBD).
Mean PAP = 4(PRVBD)2 + RAP
 • Surrogates of heart function (e.g. stroke volume index 
and cardiac index) have been shown to be associated 
with prognosis (32, 34). It is possible to estimate these 
values using echocardiography (Table  5) although the 
preferred option would be by thermodilution at RHC (2).
 • Pulmonary vascular resistance (PVR) can be measured 
using TRV (m/s) and VTIRVOT (cm):
PVR (Wood units) = 10 × (TRV/VTIRVOT) + 0.16. Here, a 
TRV/VTIRVOT <0.2 corresponds approximately to a PVR 
of <2 Wood units (35).
Table 5 Calculations to assess markers of ventricular function.
Measure Echocardiographic assessment
Cross sectional area (CSA) left ventricular outflow tract (LVOT) (LVOT diameter)2 × 0.785
Stroke volume (SV) Velocity time integral (VTI)(LVOT)  × Cross sectional area (CSA)(LVOT)
Cardiac output (CO) Stroke volume × heart rate (HR)
Stroke volume index (SVi) Stroke volume/body surface area (BSA)
Cardiac index (CI) CO/BSA
Figure 2
Measurement of pulmonary regurgitant jet at end diastole (marked X).
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Appendices
TR assessment
Peak TR velocity is the key parameter in determining the 
probability of PH, but the TR signal can be absent in a 
proportion of patients. The prevalence of TR in patients 
with a PASP ≥35 mmHg is only 80% but increases to 
greater than 95% in those with PASP >50 mmHg (36). If 
the TR signal is absent, probability estimation should be 
based on clinical context taking into consideration other 
concordant clinical and echocardiographic signs of RV 
pressure overload (Fig.  1). In patients with a trivial TR 
jet or sub optimal continuous wave Doppler spectrum, 
injection of intravenous agitated saline can be considered 
to improve the Doppler signal allowing measurement 
of peak TR velocity (37) (Fig. 3). As a default, if clinical 
suspicion remains, invasive measurement of pulmonary 
pressures should be recommended.
In patients with severe TR, TR velocity can be 
significantly underestimated and cannot be used alone 
to exclude PH. The severity of the volume of TR is 
distinct from velocity and the probability of PH in this 
context should be determined in conjunction with other 
echocardiographic parameters (Fig. 1).
Assessment of PH in patients with left heart disease
This guideline endorses the use of a probability-
based approach for the assessment of PH in all clinical 
subgroups including those secondary to left-sided 
heart disease. A full assessment including history, ECG 
and echocardiography will help to identify PH due to 
left heart disease (38). This is important as left heart 
disease will be the major aetiology of PH encountered 
in echocardiography departments (9). If there is an 
intermediate or high probability of PH then further 
echocardiographic evaluation should be made to exclude 
a cardiac cause for PH. In particular, this should prompt 
a careful assessment of LV systolic and diastolic function, 
measurement of left atrial volume and exclusion of left-
sided valve disease (Table 6). Colour flow Doppler should 
be used to exclude atrial and ventricular septal defects. 
Following a thorough clinical review, a bubble study and 
transoesophageal echocardiogram may be considered to 
fully exclude cardiac causes of PH, especially in those 
patients with confirmed PH.
It is recognised that some guidelines use an absolute 
PASP value to guide management of patients with PH 
secondary to left heart disease. In patients with severe 
Figure 3
TR jet obtained at baseline (top) is improved following injection of 
intravenous agitated saline (bottom).
Table 6 Features which may suggest left heart disease causing PH.
PH due to left heart disease group Echocardiographic features suggesting left heart disease may be cause of PH
LV systolic dysfunction Dilated LV; reduced LV ejection fraction
LV diastolic dysfunction E/e′ >10 (39); left atrial dilatation (40); left ventricular hypertrophy (38)
Valvular heart disease >Mild valvular disease
Congenital heart disease Presence of intra and extra cardiac defects
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mitral valve disease, a PASP >50 mm Hg is considered 
a class IIa indication for surgery (3, 4). Evidence for this 
is largely based on invasive pulmonary artery pressure 
measurements, but there are limited echocardiographic 
studies suggesting a prognostic role for PASP derived 
from TR velocity and RA pressure (41, 42). In this subset 
of patients, in addition to determining probability of 
PH using TR velocity, resting PASP can be estimated 
by echocardiography using standard methods (4). 
Confirmation by invasive measurement is required before 
considering valve surgery if elevated PASP is the main or 
only reason triggering intervention.
Key messages
In patients with suspected PH, the following echo 
parameters should be used to assess the probability of PH:
1. Peak TR velocity
2. Ventricle
a. Eccentricity index
b. Basal LV/RV diameter ratio
3. PA
a. RVOT acceleration time and/or mid systolic notching
b. Early diastolic PR velocity
c. PA diameter
4. RA and IVC
a. RA area
b. IVC size and respiratory variability
Conclusion
Echocardiography should be used to assess the probability 
of PH being present. Confirmation with right heart 
catheterisation is warranted if a definitive diagnosis of PH 
is needed, particularly if pre-capillary PH-specific therapies 
may be indicated.
Abbreviations
A4C Apical four chamber
AT Acceleration time
BSA Body surface area
BSE British Society of Echocardiography
CI Cardiac index
CO Cardiac output
CW Continuous wave
DT Deceleration time
EI Eccentricity index
FAC Fractional area change
HR Heart rate
IVC Inferior vena cava
IVCT Isovolumetric contraction time
IVRT Isovolumetric relaxation time
LA Left atrium
LV Left ventricle
PA Pulmonary artery
PAP Pulmonary artery pressure
PASP Pulmonary artery systolic pressure
PDP Pulmonary arterial end diastolic pressure
PH Pulmonary hypertension
PHT Pressure half-time
PR Pulmonary regurgitation
PRVBD Pulmonary regurgitant velocity at the beginning of 
diastole
PRVED Pulmonary regurgitant velocity at the end of 
diastole
PS Pulmonary stenosis
PSAX Parasternal short axis
PV Pulmonary valve
PVR Pulmonary vascular resistance
PW Pulsed wave
RA Right atrium
RAA Right atrial area
RAP Right atrial pressure
RHC Right heart catheterisation
RIMP Right ventricular index of myocardial performance
RV Right ventricle
RVAd/s Right ventricular area in diastole/systole
RVD Right ventricular diameter
RVOT Right ventricular outflow tract
RVSP Right ventricular systolic pressure
SV Stroke volume
SVi Stroke volume index
TAPSE Tricuspid annular plane systolic excursion 
TR Tricuspid regurgitation
TRV Tricuspid regurgitation velocity
TV Tricuspid valve
Vmax Maximum velocity
VTI Velocity time integral
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